ERA Official Statement
We recognize the importance of addressing the ongoing concerns surrounding the paper titled “Personalized embryo transfer reduces success rates because endometrial receptivity analysis fails to accurately identify the window of implantation” by Kevin S. Richter and Martin L. Richter. We are fully committed to supporting you and standing by your side. Our main objective is to ensure that accurate information about our services reaches everyone. We are concerned about the potential impact misinformation can have on your patients. As experts in the field, we are firmly dedicated to sharing the correct data and providing clear guidance on the appropriate use of our services.
At Igenomix, we consistently leverage scientific advancements and stay at the forefront of research to enhance the accuracy and reliability of the ERA test. The credibility of the ERA test stems from its extensive scientific validation, with numerous publications confirming its effectiveness. Since 2011, over 200,000 women worldwide have undergone the ERA test provided by Igenomix.
The ERA test has yielded proven results, with more than 20 clinical studies conducted globally supporting its utilization. It was introduced as a solution for women experiencing repeated failed embryo transfers. When applied to this specific target population, the ERA test significantly increases the chances of achieving a successful pregnancy. Our goal at Igenomix is a healthy baby at home, and we are committed to making this a reality for our patients sooner rather than later.
You are welcome to connect with our scientific community for detailed explanations and support. Rest assured that we will stand by your side and assist you in helping your patients achieve a healthy pregnancy. Contact us by using the information listed below:
era@igenomix.com
